Stockscreener 앱 받기
0.8233
0.29%
0.0009
전일 마감가:
$0.8242
열려 있는:
$0.8242
하루 거래량:
582.72K
Relative Volume:
0.98
시가총액:
$70.08M
수익:
$2.24M
순이익/손실:
$-136.67M
주가수익비율:
-0.3595
EPS:
-2.29
순현금흐름:
$-102.08M
1주 성능:
-9.17%
1개월 성능:
-17.34%
6개월 성능:
-63.75%
1년 성능:
-81.08%
1일 변동 폭
$0.7811
$0.8364
1주일 범위
$0.7811
$0.937
52주 변동 폭
$0.7811
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
IPSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.8266 | 70.08M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.80 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.37 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MyChesCo
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Century Therapeutics Unveils Advances in Cell Therapies - TipRanks
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Purchased by State Street Corp - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Declines By 5.6% - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler - Defense World
Piper Sandler supports Century shares with Overweight rating as CAR-iNK study progresses - Investing.com UK
Century Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Nigeria
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3B - The Business Journals
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com
Century Therapeutics ends collaboration with Bristol-Myers Squibb By Investing.com - Investing.com Australia
Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat
Fmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Faces Termination of BMS Agreement - TipRanks
Century Therapeutics (NASDAQ:IPSC) Trading Down 4.3%Here's Why - MarketBeat
Shelby Keating Brown Obituary (2024)Jenkintown, PAJoseph J. McGoldrick Funeral Home, Inc.Jenkintown - Legacy.com
Likelihood of Approval and Phase Transition Success Rate ModelCNTY-101 in Systemic Lupus Erythematosus - GlobalData
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Century Therapeutics to Present at Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Casdin Capital, LLC Increases Stake in Century Therapeutics Inc - GuruFocus.com
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - The Manila Times
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):